Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Efficacy of Bifidobacterium animalis subsp. lactis, BB-12® on infant colic - a randomised, double-blinded, placebo-controlled study.

  • 2021-11-16
  • Beneficial Microbes 12(6)
    • K. Chen
    • G. Zhang
    • H. Xie
    • L. You
    • H. Li
    • Y. Zhang
    • C. Du
    • S. Xu
    • C. Melsaether
    • S. Yuan

Abstract

To evaluate the administration of Bifidobacterium animalis subsp. lactis, BB-12® (BB-12) on infant colic in breastfed infants, a double-blind, placebo-controlled randomised study was conducted in Chengdu, China from April 2016 to October 2017 with 192 full-term infants less than 3 months of age and meeting the ROME III criteria for infant colic. After a 1-week run-in the infants were randomly assigned to receive daily BB-12 (1×109 cfu/day) or placebo for 3 weeks. Crying/fussing time were recorded using a 24 h structured diary. The primary endpoint was the proportion of infants achieving a reduction in crying and fussing time of ≥50% from baseline. Parent's/caregiver's health related quality of life was measured using a modified PedsQL™ 2.0 Family Impact Module and immunological biomarkers were evaluated from faecal samples at baseline and after the 21-day intervention. The percentage of infants achieving a reduction in the daily crying/fussing time ≥50% after the 21-day intervention was significantly higher in the infants supplemented with BB-12 (P<0.001). The mean number of crying episodes was significantly reduced in the BB-12 group compared to the placebo group (10.0±3.0 to 5.0±1.87 vs 10.5±2.6 to 7.5±2.8, respectively) (P<0.001) and the mean daily sleep duration was markedly increased from baseline to end of intervention in the BB-12 group compared to the infants in the placebo group (60.7±104.0 vs 31.9±102.7 min/day, respectively) (P<0.001). The faecal levels of human beta defensin 2, cathelicidin, slgA, calprotectin and butyrate were statistically higher in the BB-12 group compared to the placebo group after the 21-day intervention. At the end of the intervention the parent's/caregiver's physical, emotional and social functioning scores were significantly higher for the BB-12 group compared to the placebo group (all P<0.05). Supplementation of BB-12 is effective in reducing crying and fussing in infants diagnosed with infant colic.

Keywords: Bifidobacterium; excessive fussing and crying; probiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium bifidum BB-06Improved Immunological BiomarkersBeneficial
Moderate
Bifidobacterium bifidum BB-06Improved Parent/Caregiver Health-Related Quality of LifeBeneficial
Large
Bifidobacterium bifidum BB-06Increased Sleep Duration in InfantsBeneficial
Large
Bifidobacterium bifidum BB-06Reduced Inconsolable Crying EpisodesBeneficial
Large
Bifidobacterium bifidum/lactis Bb-02Increased Daily Sleep DurationBeneficial
Large
Bifidobacterium bifidum/lactis Bb-02Increased Fecal Immunological BiomarkersBeneficial
Moderate
Bifidobacterium bifidum/lactis Bb-02Reduced Inconsolable Crying EpisodesBeneficial
Large
Bifidobacterium lactis Bb-02Improved Parent/Caregiver Quality of LifeBeneficial
Large
Bifidobacterium lactis Bb-02Improved Sleep DurationBeneficial
Large
Bifidobacterium lactis Bb-02Increased Fecal Immunological BiomarkersBeneficial
Moderate
Bifidobacterium lactis Bb-02Reduced Inconsolable Crying EpisodesBeneficial
Large
Bifidobacterium lactis BB-12Improved Immunological BiomarkersBeneficial
Moderate
Bifidobacterium lactis BB-12Improved Parent/Caregiver Quality of LifeBeneficial
Large
Bifidobacterium lactis BB-12Increased Daily Sleep DurationBeneficial
Large
Bifidobacterium lactis BB-12Reduced Inconsolable Crying EpisodesBeneficial
Large
Bifidobacterium lactis HDS Bb-02Increased Daily Sleep DurationBeneficial
Large
Bifidobacterium lactis HDS Bb-02Increased Fecal Immunological BiomarkersBeneficial
Moderate
Bifidobacterium lactis HDS Bb-02Reduced Inconsolable Crying EpisodesBeneficial
Large
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Join Our Community
Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.